Anti-alphabeta3 humanized monoclonal antibodies
US7230083B2 · kind B2 · utility
9Cited by
1References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 20, 2002 |
| Grant date | Jun 12, 2007 |
| Priority date | — |
| Expiry date | May 18, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to the vitronectin αvβ3 receptor and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of αvβ3-mediated disorders, such as restenosis, in human patients.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.